AQP5 expression and demographic and clinopathologic characteristics of the CML patients.

*Secondary chromosomal change denotes abnormal changes detected from conventional karyotyping test other than bcr-abl amplification; t(9,22). †Time to resistance represents the interval between the days imatinib mesylate was started to the day resistance to the drug emerged. ‡P values were derived from Student's t-test (age and days to resistance) and Fisher-Freeman-Halton exact (other variables). SD denotes standard deviation.